357 related articles for article (PubMed ID: 32402935)
1. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies.
Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J
Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
4. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
5. MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding
Avilés P; Domínguez JM; Guillén MJ; Muñoz-Alonso MJ; Mateo C; Rodriguez-Acebes R; Molina-Guijarro JM; Francesch A; Martínez-Leal JF; Munt S; Galmarini CM; Cuevas C
Mol Cancer Ther; 2018 Apr; 17(4):786-794. PubMed ID: 29440297
[TBL] [Abstract][Full Text] [Related]
6. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
8. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
[TBL] [Abstract][Full Text] [Related]
9. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
10. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
11. Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment "B" analogues.
Patel VF; Andis SL; Kennedy JH; Ray JE; Schultz RM
J Med Chem; 1999 Jul; 42(14):2588-603. PubMed ID: 10411479
[TBL] [Abstract][Full Text] [Related]
12. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
14. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.
Tao Y; Wang R; Lai Q; Wu M; Wang Y; Jiang X; Zeng L; Zhou S; Li Z; Yang T; Yao Y; Wu Y; Yu L; Fu Y; Lai W; Peng Y; Lu Y; Zhang Z; Guo C; Zhang G; Gou L; Yang J
Mol Oncol; 2019 Sep; 13(9):1855-1873. PubMed ID: 31116512
[TBL] [Abstract][Full Text] [Related]
15. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
16. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
[TBL] [Abstract][Full Text] [Related]
17. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy.
Chowdari NS; Pan C; Rao C; Langley DR; Sivaprakasam P; Sufi B; Derwin D; Wang Y; Kwok E; Passmore D; Rangan VS; Deshpande S; Cardarelli P; Vite G; Gangwar S
Bioorg Med Chem Lett; 2019 Feb; 29(3):466-470. PubMed ID: 30579797
[TBL] [Abstract][Full Text] [Related]
18. Novel trastuzumab-DM1 conjugate: Synthesis and bio-evaluation.
Abedi M; Cohan RA; Mahboudi F; Faramarzi MA; Fazel R; Damavandi N; Ardestani MS; Davami F
J Cell Physiol; 2019 Aug; 234(10):18206-18213. PubMed ID: 30854662
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
[TBL] [Abstract][Full Text] [Related]
20. Conformational changes in tubulin upon binding cryptophycin-52 reveal its mechanism of action.
Eren E; Watts NR; Sackett DL; Wingfield PT
J Biol Chem; 2021 Oct; 297(4):101138. PubMed ID: 34461087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
